Literature DB >> 16237386

Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women.

Andrea Gogos1, Pradeep J Nathan, Valérie Guille, Rodney J Croft, Maarten van den Buuse.   

Abstract

The sex steroid hormone, estrogen, has been proposed to be protective against schizophrenia. This study examined the effects of estrogen treatment on modulation of prepulse inhibition (PPI) by the serotonin-1A (5-HT1A) receptor partial agonist, buspirone. PPI is a model of sensorimotor gating, which is deficient in schizophrenia and other mental illnesses. A total of 11 healthy women were tested following four acute treatment conditions: placebo, buspirone (Buspar; 5 mg), estradiol (Estrofem; 2 mg), and combined buspirone and estradiol. Electromyogram activity was measured across three interstimulus intervals (ISI): 30, 60, and 120 ms. There was no significant effect of either drug treatment on startle amplitude or habituation. At 120 ms ISI, buspirone caused a significant disruption of PPI and pretreatment with estrogen prevented this disruption. Estrogen treatment, administered in the appropriate experimental conditions, prevented PPI deficits induced by 5-HT(1A) receptor activation and may therefore also play a protective role in sensorimotor gating deficits in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16237386     DOI: 10.1038/sj.npp.1300933

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  19 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

2.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  The effects of ethinylestradiol and progestins ("the pill") on cognitive function in pre-menopausal women.

Authors:  Andrea Gogos; YeeWen Candace Wu; Amy S Williams; Linda K Byrne
Journal:  Neurochem Res       Date:  2014-09-30       Impact factor: 3.996

4.  Oestrogen modulation of the effect of 8-OH-DPAT on prepulse inhibition: effects of aromatase deficiency and castration in mice.

Authors:  Andrea Gogos; Sally Martin; Margaret E Jones; Maarten van den Buuse
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

5.  Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice.

Authors:  Marie A Labouesse; Wolfgang Langhans; Urs Meyer
Journal:  Psychopharmacology (Berl)       Date:  2015-04-18       Impact factor: 4.530

6.  Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT(1A), but not 5-HT₂ receptor activation.

Authors:  Roberto Stancampiano; Roberto Frau; Valentina Bini; Maria Collu; Manolo Carta; Fabio Fadda; Marco Bortolato
Journal:  Eur Neuropsychopharmacol       Date:  2012-11-06       Impact factor: 4.600

Review 7.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

8.  The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia.

Authors:  Andrea Gogos; Perrin Kwek; Maarten van den Buuse
Journal:  Psychopharmacology (Berl)       Date:  2011-07-29       Impact factor: 4.530

9.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

Review 10.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.